MEA Cancer Vaccines Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 9.60 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
MEA Cancer Vaccines Market Analysis
The Middle East and Africa cancer vaccine market is expected to register a CAGR of 9.6% during the forecast period.
- COVID-19 significantly impacted the Middle East and African cancer vaccine market since there occurred a delay in the development and availability of cancer vaccines in the studied region due to the lockdown restrictions. As per the article published in October 2021 in PubMed, to make the best use of the limited resources for cancer management in COVID-19 epidemic settings, oncology centers and institutes across the region created clinical practice guidelines and recommendations.
- Additionally, the pandemic affected African cancer screening and diagnostic programs. Cancer screening programs (including mammograms and pap smears) were discontinued in Morocco due to the early rise in COVID-19 cases. However, as the restrictions are lifted, and the pandemic spread reduced, the cancer vaccine market in the Middle East and Africa is expected to witness significant growth due to the rise in cancer cases and the increase in research development in cancer vaccines.
- Factors such as the high prevalence of cancer cases, the increase in cancer vaccine development, and the rise in demand for cancer vaccines across the region are expected to drive market growth. According to IARC estimations, the number of new cancer cases in Africa is estimated to be 1.5 million by 2030. This number is likely to rise to 2.1 million by 2040.
- Furthermore, strategic activities like partnerships, acquisitions, and mergers by key players are expected to increase product availability, which is likely to drive market growth over the forecast period. For instance, in February 2022, Pfizer renewed its partnerships with United Arab Emirates-based cancer patient societies Friends of Cancer Patients (FOCP) and Emirates Oncology Society to mark World Cancer Day. The pharmaceutical company has reinforced its commitment to advance oncology care, encourage early detection, and support cancer treatment in the country.
- Further, in January 2022, South African-born United States billionaire Patrick Soon-Shiong and South African President Cyril Ramaphosa opened a new vaccine manufacturing plant for cancer and COVID-19 vaccine in Cape Town. It aimed to hasten the domestic production of pharmaceuticals and vaccines that will reach patients across the African continent.
- Hence, considering the high prevalence of cancer cases and the increase in strategic activities by the key players, the studied market is expected to witness fair growth over the forecast period. However, adopting alternative therapies in cancer treatment is expected to hinder market growth.
MEA Cancer Vaccines Market Trends
Cervical Cancer Segment is Expected to Witness a Significant Growth in the Market Over the Forecast Period
- Cervical cancer is cancer of the cells in the cervix. The rising burden of cervical cancer, increasing awareness, and government initiatives across the Middle East and Africa region are propelling the growth of the segment. For instance, in October 2022, the Government of Sierra Leone introduced the Human Papillomavirus (HPV) vaccine to the routine immunization schedule and launched the start of a campaign to reach 153,991 girls with the vaccine. The introduction of the HPV vaccine is one of the key strategies that the government is implementing for cervical cancer elimination in the country.
- Furthermore, the high prevalence of cervical cancer in Africa and GCC is expected to utilize the cancer vaccine market over the forecast period. For instance, as per the IARC estimations, 188.6 thousand cases of cervical cancer are estimated to be diagnosed in Africa and GCC in 2035. This number is likely to rise to 219.1 thousand by 2040. Moreover, strategic activities like partnerships, product launches, and mergers by the key players are expected to fuel market growth.
- For instance, in November 2022, AstraZeneca teamed up with a host of African organizations to help patients across the continent gain better and more fair access to cancer care. The program was led by a steering committee of doctors, oncology institutions, and advocacy groups to guide policy intervention, share lessons across borders, and put cancer patients at the center.
- Furthermore, an increase in awareness programs regarding the treatment and diagnosis of cervical cancer is expected to drive market growth over the forecast period. For instance, in November 2021, Saudi Arabia launched an HPV vaccination program for girls aged 9-13. Although HPV can come in 100 different variants, certain types are categorized as high-risk.
- A 2021 HPV Information Centre study showed that approximately 358 new cervical cancer cases are diagnosed annually in Saudi Arabia, where cervical cancer ranks as the eighth most common cause of female cancer in women aged 15 to 44. Hence, considering the high prevalence of cervical cancer cases and the increase in cervical cancer vaccine launches, and the surge in awareness campaigns by the government, the studied segment is expected to witness fair growth over the forecast period.
GCC is Expected to Hold a Notable Share in the Market Over the Forecast Period
The Gulf Cooperation Council (GCC) region comprises the United Arab Emirates, Saudi Arabia, Qatar, Oman, Kuwait, and Bahrain. The factors such as the growing burden of cancer cases, increasing focus on research, and development of novel therapeutics are expected to drive market growth in GCC countries. Also, a rise in government initiatives and an increase in investment in healthcare are expected to bolster market growth over the forecast period. For instance, in April 2022, Dante Labs, a company in genomics and precision medicine was selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC), the Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine. In parallel, a joint R&D program has been launched focused on the development of an mRNA vaccine platform to identify individual cancer treatments.
Moreover, according to the IARC estimations, around 69.1 thousand new cancer cases are likely to be reported in GCC by 2030 and this number is estimated to rise to 104.4 thousand by 2040. The rising prevalence of cancer will boost the demand for cancer vaccines and further drive market growth. Thus, owing to the abovementioned factors, the studied market is expected to grow over the forecast period in the GCC region.
Furthermore, as per the article published in November 2022 in PubMed, the study was conducted on 805 Omani women in which approximately one-third of the women identified HPV as a risk factor for developing cervical cancer (38.9%). Very few participants knew of HPV vaccines (10.1%). Hence, the low awareness of the HPV virus and its prevention across the GCC is expected to drive market growth over the forecast period. Additionally, in February 2022, Aster Hospitals UAE launched a cancer support group coinciding with World Cancer Day on February 4, observed every year. Aster Hospitals also opened a state-of-the-art Department of Oncology at Aster Hospital Al Qusais, Dubai in 2021. The cancer support group was launched under the broader patient support entity, Aster Cosmos. Hence, thus due to the high prevalence of cancer cases and the increase in cancer awareness programs and conferences by the government, GCC is expected to hold a major share of the market over the forecast period.
MEA Cancer Vaccines Industry Overview
The Middle East and African cancer vaccines market is fragmented with several major players. Some of the strategies implemented include agreements, collaborative models, business expansion, and product development. Some of the key players are Astellas Pharma Inc., AstraZeneca PLC, Merck & Co. Inc, GlaxoSmithKline, and Bristol-Myers Squibb.
MEA Cancer Vaccines Market Leaders
-
AstraZeneca PLC
-
Merck & Co. Inc.
-
Bristol-Myers Squibb
-
Astellas Pharma Inc.
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
MEA Cancer Vaccines Market News
- December 2022: Cancer Moonshot publicized new actions aimed at reducing the cancer burden in Africa as part of the United States-Africa Leaders Summit. The Cancer Moonshot highlights bold deliverables and new announcements from U.S. departments and agencies and the private sector of over USD 300 million to drastically improve cancer outcomes in Africa.
- April 2022: Dante Labs reported that the company was selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines. Dante and the ADSCC will partner on the launch of an R&D program with a focus on personalized treatments for oncology patients and, eventually, the development of cancer vaccines.
MEA Cancer Vaccines Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cancer Cases
4.2.2 Rise in Research and Developments in Cancer Vaccines
4.3 Market Restraints
4.3.1 Presence of Alternative Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD million)
5.1 By Technology
5.1.1 Recombinant Cancer Vaccines
5.1.2 Whole-cell Cancer Vaccines
5.1.3 Viral Vector and DNA Cancer Vaccines
5.1.4 Other Technologies
5.2 By Treatment Method
5.2.1 Preventive Vaccine
5.2.2 Therapeutic Vaccine
5.3 By Application
5.3.1 Prostate Cancer
5.3.2 Cervical Cancer
5.3.3 Other Applications
5.4 Geography
5.4.1 GCC
5.4.2 South Africa
5.4.3 Rest of Middle East and Africa
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc.
6.1.2 AstraZeneca PLC
6.1.3 Merck KGaA
6.1.4 GSK
6.1.5 Bristol-Myers Squibb
6.1.6 Dendreon
6.1.7 Sanofi
6.1.8 Creative Biolabs
6.1.9 Biopharma Middle East & Africa
6.1.10 Pfizer
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
MEA Cancer Vaccines Industry Segmentation
As per the scope of the report, cancer vaccines are defined as vaccines developed to prevent or treat existing cancers by strengthening the body's natural immune response system against cancer. These cancer vaccines belong to a class of substances known as biological response modifiers.
The Middle East and Africa cancer vaccine market is segmented by technology (recombinant cancer vaccines, whole-cell cancer vaccines, viral vector & DNA cancer vaccines, other technologies), treatment method (preventive vaccine and therapeutic vaccine), application (prostate cancer, cervical cancer, other applications) and geography (GCC, South Africa, Rest of Middle East and Africa).
The report offers the value (in USD million) for the above segments.
| By Technology | |
| Recombinant Cancer Vaccines | |
| Whole-cell Cancer Vaccines | |
| Viral Vector and DNA Cancer Vaccines | |
| Other Technologies |
| By Treatment Method | |
| Preventive Vaccine | |
| Therapeutic Vaccine |
| By Application | |
| Prostate Cancer | |
| Cervical Cancer | |
| Other Applications |
| Geography | |
| GCC | |
| South Africa | |
| Rest of Middle East and Africa |
MEA Cancer Vaccines Market Research FAQs
What is the current MEA Cancer Vaccines Market size?
The MEA Cancer Vaccines Market is projected to register a CAGR of 9.60% during the forecast period (2024-2029)
Who are the key players in MEA Cancer Vaccines Market?
AstraZeneca PLC, Merck & Co. Inc., Bristol-Myers Squibb, Astellas Pharma Inc. and GSK plc are the major companies operating in the MEA Cancer Vaccines Market.
What years does this MEA Cancer Vaccines Market cover?
The report covers the MEA Cancer Vaccines Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the MEA Cancer Vaccines Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Middle East and Africa Cancer Vaccines Industry Report
Statistics for the 2024 MEA Cancer Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MEA Cancer Vaccines analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
